Lipoxygenase Pathways as Mediators of Early Inflammatory Events in Atherosclerosis
2006; Lippincott Williams & Wilkins; Volume: 26; Issue: 6 Linguagem: Inglês
10.1161/01.atv.0000222960.43792.ff
ISSN1524-4636
Autores Tópico(s)Inflammatory mediators and NSAID effects
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 26, No. 6Lipoxygenase Pathways as Mediators of Early Inflammatory Events in Atherosclerosis Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBLipoxygenase Pathways as Mediators of Early Inflammatory Events in Atherosclerosis Colin D. Funk Colin D. FunkColin D. Funk From the Departments of Physiology and Biochemistry, Queen's University, Kingston, Canada. Originally published1 Jun 2006https://doi.org/10.1161/01.ATV.0000222960.43792.ffArteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1204–1206Oxidative modification of low density lipoproteins has been a leading hypothesis in atherogenesis, and throughout the 1990's there was intense interest in the discovery of pathways leading to this modification.1,2 In a commentary to an article dealing with 12/15-lipoxygenase gene disruption in the atherosclerotic apolipoprotein E (apoE)-deficient mouse model in 1999, Daniel Steinberg declared "at last direct evidence that lipoxygenases play a role in atherosclerosis."3,4 Since this article seven years ago, the lipoxygenase pathway involvement in atherogenesis has become rather more complicated.See page 1260Lipoxygenases are non-heme iron–containing enzymes that catalyze the stereospecific incorporation of molecular oxygen into polyunsaturated fatty acids with a 1,4-cis, cis-pentadiene motif.5 With respect to atherosclerosis 2 of the 6 (human)/7 (mice) lipoxygenase family members have received the most attention because of their expression patterns in inflammatory cells and in some settings within endothelial cells; these are the 12/15-lipoxygenase (12/15-LO; also known as the leukocyte-type 12-lipoxygenase and 15-lipoxygenase-1) and 5-lipoxygenase.6,7 12/15-LO catalyzes the transformation of free arachidonic acid to 12-hydroperoxy-eicosatetraenoic acid (12-HPETE) and 15-HPETE. These products are reduced to the corresponding hydroxy derivatives 12-HETE and 15-HETE by cellular peroxidases. Mice make predominantly 12-HETE whereas humans produce mainly 15-HETE. Both human and mouse 12/15-LO enzymes metabolize linoleic acid to 13-hydroperoxy-octadecadienoic acid (13-HPODE; the reduced product is 13-HODE) as well as metabolizing more complex lipids including cholesteryl linoleate and sn2 polyunsaturated fatty acids within phospholipids. Thus, 12/15-LO has been shown to oxidatively modify the key lipid components of LDL. 5-Lipoxygenase, on the other hand, only metabolizes free arachidonic acid leading to the formation of proinflammatory leukotrienes and cannot participate in the direct oxidative modification of LDL.6,7The ability to generate oxidatively-modified LDL by 12/15-LO is only one potential mechanism for its atherogenic promoting role. 12/15-LO can also modulate the expression of a key proinflammatory proatherosclerotic Th1 cytokine, interleukin (IL)-12.8 Hedrick and colleagues9–11 have been following a line of studies over the past 7 years indicating that 12/15-LO can also enhance the adhesion of monocytes to endothelial cells, an early event in atherogenesis. In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, these researchers further our understanding of the intracellular pathways involved in the 12/15-LO-mediated monocyte adhesion events.12 Using 12/15-LO knockout mice cross-bred to apoE-deficient mice, they demonstrate a dramatic reduction of monocyte binding to endothelial cells derived from these mice. A lipoxygenase inhibitor, CDC (cinnamyl-3,4-dihydroxy-α -cyanocinnamate), mimics the effect observed by gene disruption. The monocyte adhesion appears to be mediated primarily by intercellular adhesion molecule-1 (ICAM-1), and previous work by this group9 also demonstrated the importance of the fibronectin isoform containing connecting segment-1 in monocyte adhesion. Here, and in another recent publication,11 they show that the 12/15-LO product, 12(S)-HETE, but not the stereoisomer 12(R)-HETE, mediates the ICAM-1 induction through a G protein (G12/13), RhoA, protein kinase Cα, NF-κB activation pathway (see the Figure). The authors postulate that the 12/15-LO product can activate a G protein–coupled receptor (GPCR) to initiate these events. The isolation of this receptor has proven elusive. With the full complement of human GPCRs cloned and expressed it is surprising that no research group has "adopted" one of the orphan members as a 12-HETE receptor. Others have demonstrated the capacity of 12-HETE to bind an intracellular receptor that complexes with other proteins, which is more reminiscent of nuclear hormone signaling.13,14 In any case, knowing the pathway of activation from 12-HETE synthesis to ICAM-1 induction and monocyte adhesion is a significant step forward in determining molecular eicosanoid signaling translated to vascular biological activities. The authors' work with both 12/15-LO overexpressing endothelial cells from transgenic mice10,11 and experiments with 12/15-LO deficient mouse-derived endothelial cells12 provide a compelling argument for this mode of signaling. Download figureDownload PowerPointProposed signaling pathway in endothelial cells from 12/15-LO mediated conversion of arachidonic acid (20:4) to activation of monocyte adhesion. In mice, a mixture of two hydroperoxides results from this conversion (12-HPETE and 15-HPETE). Cellular peroxidases reduce these to the corresponding HETE molecules. Generation of the stereoisomer 12(S)-HETE predominates in a ≈4:1 ratio and is the likely ligand for activation of a putative HETE receptor and signaling through the G protein G12/13 to a pathway consisting of RhoA, protein kinase C, and nuclear factor κB transcription factor activation that leads to enhanced intercellular adhesion molecule-1 surface endothelial expression that can promote monocyte binding to the endothelial cell layer. This is a potential pathway that can explain some of the proinflammatory events of the 12/15-LO pathway in atherosclerosis.The next important step will be to establish the connection between the enhanced ICAM-1 induction by 12(S)-HETE and atherogenesis. The case for ICAM-1 involvement in mediating early atherogenic events is unclear with some groups reporting that ICAM-1 deficiency reduces lesion development in apoE-deficient mice,15,16 whereas another team of investigators contends evidence that vascular cell adhesion molecule (VCAM)-1, but not ICAM-1, is important in early atherogenesis.17 Returning to the complicated area of lipoxygenases in atherosclerosis mentioned in the first paragraph, the role for 12/15-LO in atherogenesis has been verified in three different mouse models (apoE, LDL-R, and apobec-1/LDL-R deficiency) by at least three research groups and studies suggest a role for 12/15-LO expressing bone marrow–derived cells (eg, macrophages) in preference to endothelial cells in the proatherogenic role.4,8,18,19 However, other investigators have shown that the human 15-LO pathway and transgenic 15-LO macrophage overexpressing rabbits may contribute antiinflammatory compounds like lipoxins and lead to a reduction in atherosclerosis.20,21 To further complicate matters there have been a substantial number of studies in the past few years implicating the 5-LO pathway in atherogenesis in humans and mice with a large number of inconsistencies between studies (reviewed in refs. 22, 23). 5-LO–derived leukotriene B4 appears to influence early atherosclerotic events in mouse studies perhaps also by mediating monocyte adhesion and recruitment via monocyte chemoattractant protein-1 (MCP-1).24–27 However, lesion development resulting from complete loss of leukotriene biosynthesis (both LTB4 and the cysteinyl leukotrienes LTC4, LTD4, and LTE4) does not appear to substantially impact atherosclerosis in a variety of fat feeding and mid-to-long–term experiments in both apoE- and LDL-R–deficient states.28Integrating the biological activities of the 5-LO and 12/15-LO pathways into a unified paradigm for early atherogenic events should be the goal for researchers in this area over the next few years. Hedrick and colleagues' experiments to elucidate the intracellular signaling events in the 12/15-LO pathway are important steps forward toward this goal.This work was supported by grants from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Ontario. C.F. is a holder of a Tier I Canada Research Chair in Molecular, Cellular, and Physiological Medicine and Career Investigator Award from the Heart and Stroke Foundation of Canada.FootnotesCorrespondence to Colin Funk, Department of Physiology, Stuart Street, Queen's University, Kingston, ON K7L 3N6 Canada. E-mail [email protected] References 1 Parthasarathy S, Steinberg D, Witztum JL. The role of oxidized low-density lipoproteins in the pathogenesis of atherosclerosis. Annu Rev Med. 1992; 43: 219–225.CrossrefMedlineGoogle Scholar2 Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996; 20: 707–727.CrossrefMedlineGoogle Scholar3 Steinberg D. At last, direct evidence that lipoxygenases play a role in atherogenesis. J Clin Invest. 1999; 103: 1487–1488.CrossrefMedlineGoogle Scholar4 Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of 12/15-lipoxygenase results in inhibition of atherosclerotic lesion development in mice lacking apolipoprotein E. J Clin Invest. 1999; 103: 1597–1604.CrossrefMedlineGoogle Scholar5 Brash AR. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J Biol Chem. 1999; 274: 23679–23682.CrossrefMedlineGoogle Scholar6 Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med. 2004; 14: 191–195.CrossrefMedlineGoogle Scholar7 Zhao, L, Funk, C.D. Lipoxygenases: potential therapeutic target in atherosclerosis, pp. 207–218. In: Advances in Translational Medical Science; Lipids and Atherosclerosis, eds. Packard CJ, Rader DJ. London: Taylor and Francis; 2006.Google Scholar8 Zhao L, Cuff CA, Moss E, Wille U, Cyrus T, Klein EA, Pratico D, Rader DJ, Hunter CA, Pure E, Funk CD. Selective interleukin-12 synthesis defect in 12/15-lipoxygenase-deficient macrophages associated with reduced atherosclerosis in a mouse model of familial hypercholesterolemia. J Biol Chem. 2002; 277: 35350–35356.CrossrefMedlineGoogle Scholar9 Patricia MK, Kim JA, Harper CM, Shih PT, Berliner JA, Natarajan R, Nadler JL, Hedrick CC. Lipoxygenase products increase monocyte adhesion to human aortic endothelial cells. Arterioscler Thromb Vasc Biol. 1999; 19: 2615–2622.CrossrefMedlineGoogle Scholar10 Reilly KB, Srinivasan S, Hatley ME, Patricia MK, Lannigan J, Bolick DT, Vandenhoff G, Pei H, Natarajan R, Nadler JL, Hedrick CC. 12/15-Lipoxygenase activity mediates inflammatory monocyte/endothelial interactions and atherosclerosis in vivo. J Biol Chem. 2004; 279: 9440–9450.CrossrefMedlineGoogle Scholar11 Bolick DT, Orr AW, Whetzel A, Srinivasan S, Hatley ME, Schwartz MA, Hedrick CC. 12/15-lipoxygenase regulates intercellular adhesion molecule-1 expression and monocyte adhesion to endothelium through activation of RhoA and nuclear factor-kappaB. Arterioscler Thromb Vasc Biol. 2005; 25: 2301–2307.LinkGoogle Scholar12 Bolick DT, Srinivasan S, Whetzel A, Fuller LC, Hedrick CC 12/15 Lipoxygenase mediates monocyte adhesion to aortic endothelium in apolipoprotein E-deficient mice through activation of RhoA and NFκB. Arterioscler Thromb Vasc Biol. 2006; 26: 1260–1266.LinkGoogle Scholar13 Herbertsson H, Kuhme T, Hammarstrom S. The 650-kDa 12(S)-hydroxyeicosatetraenoic acid binding complex: occurrence in human platelets, identification of hsp90 as a constituent, and binding properties of its 50-kDa subunit. Arch Biochem Biophys. 1999; 367: 33–38.CrossrefMedlineGoogle Scholar14 Kurahashi Y, Herbertsson H, Soderstrom M, Rosenfeld MG, Hammarstrom S. A 12(S)-hydroxyeicosatetraenoic acid receptor interacts with steroid receptor coactivator-1. Proc Natl Acad Sci U S A. 2000; 97: 5779–5783.CrossrefMedlineGoogle Scholar15 Bourdillon MC, Poston RN, Covacho C, Chignier E, Bricca G, McGregor JL. ICAM-1 deficiency reduces atherosclerotic lesions in double-knockout mice (ApoE(−/−)/ICAM-1(−/−)) fed a fat or a chow diet. Arterioscler Thromb Vasc Biol. 2000; 20: 2630–2635.CrossrefMedlineGoogle Scholar16 Collins RG, Velji R, Guevara NV, Hicks MJ, Chan L, Beaudet AL. P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2000; 191: 189–194.CrossrefMedlineGoogle Scholar17 Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, Davis V, Gutierrez-Ramos JC, Connelly PW, Milstone DS. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001; 107: 1255–1262.CrossrefMedlineGoogle Scholar18 George J, Afek A, Shaish A, Levkovitz H, Bloom N, Cyrus T, Zhao L, Funk CD, Sigal E, Harats D. 12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice. Circulation. 2001; 104: 1646–1650.CrossrefMedlineGoogle Scholar19 Huo Y, Zhao L, Hyman MC, Shashkin P, Harry BL, Burcin T, Forlow SB, Stark MA, Smith DF, Clarke S, Srinivasan S, Hedrick CC, Pratico D, Witztum JL, Nadler JL, Funk CD, Ley K. Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2004; 110: 2024–2031.Erratum in: Circulation. 2004;110:3156.LinkGoogle Scholar20 Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001; 2: 612–619.CrossrefMedlineGoogle Scholar21 Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim HS, Kuhn H, Guevara NV, Chan L. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest. 1996; 98: 2201–2208.CrossrefMedlineGoogle Scholar22 Funk CD. Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat Rev Drug Discov. 2005; 4: 664–672.CrossrefMedlineGoogle Scholar23 Lotzer K, Funk CD, Habenicht AJ. The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochim Biophys Acta. 2005; 1736: 30–37.MedlineGoogle Scholar24 Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002; 22: 443–449.CrossrefMedlineGoogle Scholar25 Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, Ali H, Tseng MT, Haribabu B. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004; 24: 369–375.LinkGoogle Scholar26 Heller EA, Liu E, Tager AM, Sinha S, Roberts JD, Koehn SL, Libby P, Aikawa ER, Chen JQ, Huang P, Freeman MW, Moore KJ, Luster AD, Gerszten RE. Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation. 2005; 112: 578–586.LinkGoogle Scholar27 Huang L, Zhao A, Wong F, Ayala JM, Struthers M, Ujjainwalla F, Wright SD, Springer MS, Evans J, Cui J. Leukotriene B4 strongly increases monocyte chemoattractant protein-1 in human monocytes. Arterioscler Thromb Vasc Biol. 2004; 24: 1783–1788.LinkGoogle Scholar28 Zhao L, Moos MP, Grabner R, Pedrono F, Fan J, Kaiser B, John N, Schmidt S, Spanbroek R, Lotzer K, Huang L, Cui J, Rader DJ, Evans JF, Habenicht AJ, Funk CD. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med. 2004; 10: 966–973.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Perry S, van Hoorebeke C, Sorrentino J, Bautista L, Akinkugbe O, Conrad W, Rutz N and Holman T (2022) Structural basis for altered positional specificity of 15-lipoxygenase-1 with 5S-HETE and 7S-HDHA and the implications for the biosynthesis of resolvin E4, Archives of Biochemistry and Biophysics, 10.1016/j.abb.2022.109317, 727, (109317), Online publication date: 1-Sep-2022. Tsai W, Gilbert N, Ohler A, Armstrong M, Perry S, Kalyanaraman C, Yasgar A, Rai G, Simeonov A, Jadhav A, Standley M, Lee H, Crews P, Iavarone A, Jacobson M, Neau D, Offenbacher A, Newcomer M and Holman T (2021) Kinetic and structural investigations of novel inhibitors of human epithelial 15-lipoxygenase-2, Bioorganic & Medicinal Chemistry, 10.1016/j.bmc.2021.116349, 46, (116349), Online publication date: 1-Sep-2021. Gilbert N, Newcomer M and Werz O (2021) Untangling the web of 5-lipoxygenase-derived products from a molecular and structural perspective: The battle between pro- and anti-inflammatory lipid mediators, Biochemical Pharmacology, 10.1016/j.bcp.2021.114759, 193, (114759), Online publication date: 1-Nov-2021. Ayola-Serrano N, Roy N, Fathah Z, Anwar M, Singh B, Ammar N, Sah R, Elba A, Utt R, Pecho-Silva S, Rodriguez-Morales A, Dhama K and Quraishi S (2021) The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications, Inflammation Research, 10.1007/s00011-021-01473-y, 70:8, (877-889), Online publication date: 1-Aug-2021. Dong C, Liu S, Cui Y and Guo Q (2020) 12-Lipoxygenase as a key pharmacological target in the pathogenesis of diabetic nephropathy, European Journal of Pharmacology, 10.1016/j.ejphar.2020.173122, 879, (173122), Online publication date: 1-Jul-2020. Taghizadeh E, Taheri F, Renani P, Reiner Ž, Navashenaq J and Sahebkar A Macrophage: A Key Therapeutic Target in Atherosclerosis?, Current Pharmaceutical Design, 10.2174/1381612825666190830153056, 25:29, (3165-3174) Halade G, Black L and Verma M (2018) Paradigm shift – Metabolic transformation of docosahexaenoic and eicosapentaenoic acids to bioactives exemplify the promise of fatty acid drug discovery, Biotechnology Advances, 10.1016/j.biotechadv.2018.02.014, 36:4, (935-953), Online publication date: 1-Jul-2018. Kaur N, Singh J and Reddy S (2017) Interaction between ALOX15 polymorphisms and coronary artery disease in North Indian population , Clinical and Experimental Hypertension, 10.1080/10641963.2017.1384485, 40:4, (398-405), Online publication date: 19-May-2018. Holzner S, Brenner S, Atanasov A, Senfter D, Stadler S, Nguyen C, Fristiohady A, Milovanovic D, Huttary N, Krieger S, Bago-Horvath Z, de Wever O, Tentes I, Özmen A, Jäger W, Dolznig H, Dirsch V, Mader R, Krenn L and Krupitza G (2018) Intravasation of SW620 colon cancer cell spheroids through the blood endothelial barrier is inhibited by clinical drugs and flavonoids in vitro, Food and Chemical Toxicology, 10.1016/j.fct.2017.11.015, 111, (114-124), Online publication date: 1-Jan-2018. Yektaei-Karin E, Zovko A, Nilsson A, Näsman-Glaser B, Kanter L, Rådmark O, Wallvik J, Ekblom M, Dolinska M, Qian H and Stenke L (2016) Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia, Leukemia & Lymphoma, 10.1080/10428194.2016.1262029, 58:8, (1903-1913), Online publication date: 3-Aug-2017. Maciejewska D, Michalczyk M, Czerwińska-Rogowska M, Banaszczak M, Ryterska K, Jakubczyk K, Piotrwski J, Hołowko J, Drozd A, Wysokińki P, Ficek K, Wilk K, Lubkowska A, Cięszczyk P, Bertrand J and Stachowska E (2017) Seeking Optimal Nutrition for Healthy Body Mass Reduction Among Former Athletes, Journal of Human Kinetics, 10.1515/hukin-2017-0090, 60:1, (63-75), Online publication date: 28-Dec-2017., Online publication date: 2-Dec-2017. Ibrahim A, Saleh H, El-Shafey M, Hussein K, El-Masry K, Baban B, Sheibani N, Wang M, Tawfik A and Al-Shabrawey M (2017) Targeting of 12/15-Lipoxygenase in retinal endothelial cells, but not in monocytes/macrophages, attenuates high glucose-induced retinal leukostasis, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 10.1016/j.bbalip.2017.03.010, 1862:6, (636-645), Online publication date: 1-Jun-2017. Ribeiro E, Greco L, Bisinotto R, Lima F, Thatcher W and Santos J (2016) Biology of Preimplantation Conceptus at the Onset of Elongation in Dairy Cows1, Biology of Reproduction, 10.1095/biolreprod.115.134908, 94:4, Online publication date: 1-Apr-2016. Armstrong M, Freedman C, Jung J, Zheng Y, Kalyanaraman C, Jacobson M, Simeonov A, Maloney D, van Leyen K, Jadhav A and Holman T (2016) A potent and selective inhibitor targeting human and murine 12/15-LOX, Bioorganic & Medicinal Chemistry, 10.1016/j.bmc.2016.01.042, 24:6, (1183-1190), Online publication date: 1-Mar-2016. Bojic L, McLaren D, Harms A, Hankemeier T, Dane A, Wang S, Rosa R, Previs S, Johns D and Castro-Perez J (2015) Quantitative profiling of oxylipins in plasma and atherosclerotic plaques of hypercholesterolemic rabbits, Analytical and Bioanalytical Chemistry, 10.1007/s00216-015-9105-4, 408:1, (97-105), Online publication date: 1-Jan-2016. Emeto T, Moxon J, Au M and Golledge J (2016) Oxidative stress and abdominal aortic aneurysm: potential treatment targets, Clinical Science, 10.1042/CS20150547, 130:5, (301-315), Online publication date: 1-Mar-2016. Sukhanov S, Snarski P, Vaughn C, Lobelle-Rich P, Kim C, Higashi Y, Shai S and Delafontaine P (2015) Insulin-like growth factor I reduces lipid oxidation and foam cell formation via downregulation of 12/15-lipoxygenase, Atherosclerosis, 10.1016/j.atherosclerosis.2014.12.024, 238:2, (313-320), Online publication date: 1-Feb-2015. Garrido-Urbani S, Meguenani M, Montecucco F and Imhof B (2013) Immunological aspects of atherosclerosis, Seminars in Immunopathology, 10.1007/s00281-013-0402-8, 36:1, (73-91), Online publication date: 1-Jan-2014. Kobe M, Neau D, Mitchell C, Bartlett S and Newcomer M (2014) The Structure of Human 15-Lipoxygenase-2 with a Substrate Mimic, Journal of Biological Chemistry, 10.1074/jbc.M113.543777, 289:12, (8562-8569), Online publication date: 1-Mar-2014. Dzoyem J, Kuete V, McGaw L and Eloff J (2014) The 15-lipoxygenase inhibitory, antioxidant, antimycobacterial activity and cytotoxicity of fourteen ethnomedicinally used African spices and culinary herbs, Journal of Ethnopharmacology, 10.1016/j.jep.2014.08.007, 156, (1-8), Online publication date: 1-Oct-2014. Kundumani-Sridharan V, Dyukova E, Hansen D and Rao G (2013) 12/15-Lipoxygenase Mediates High-fat Diet-induced Endothelial Tight Junction Disruption and Monocyte Transmigration, Journal of Biological Chemistry, 10.1074/jbc.M113.453290, 288:22, (15830-15842), Online publication date: 1-May-2013. Hopkins P (2013) Molecular Biology of Atherosclerosis, Physiological Reviews, 10.1152/physrev.00004.2012, 93:3, (1317-1542), Online publication date: 1-Jul-2013. Singh P and Pooja (2013) N-1, C-3 substituted indoles as 5-LOX inhibitors—In vitro enzyme immunoaasay, mass spectral and molecular docking investigations, Bioorganic & Medicinal Chemistry Letters, 10.1016/j.bmcl.2012.12.068, 23:5, (1433-1437), Online publication date: 1-Mar-2013. Connelly P, Picardo C, Potter P, Teiber J, Maguire G and Ng D (2011) Mouse serum paraoxonase-1 lactonase activity is specific for medium-chain length fatty acid lactones, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 10.1016/j.bbalip.2010.10.002, 1811:1, (39-45), Online publication date: 1-Jan-2011. Schurmann K, Anton M, Ivanov I, Richter C, Kuhn H and Walther M (2011) Molecular Basis for the Reduced Catalytic Activity of the Naturally Occurring T560M Mutant of Human 12/15-Lipoxygenase That Has Been Implicated in Coronary Artery Disease, Journal of Biological Chemistry, 10.1074/jbc.M110.211821, 286:27, (23920-23927), Online publication date: 1-Jul-2011. Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Schneckenleithner C, Wolbank S, Bartel G, Krieger S, Kalt R, Hantusch B, Keller T, Nagy-Bojarszky K, Huttary N, Raab I, Lackner K, Krautgasser K, Schachner H, Kaserer K, Rezar S, Madlener S, Vonach C, Davidovits A, Nosaka H, Hämmerle M, Viola K, Dolznig H, Schreiber M, Nader A, Mikulits W, Gnant M, Hirakawa S, Detmar M, Alitalo K, Nijman S, Offner F, Maier T, Steinhilber D and Krupitza G (2011) Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse, Journal of Clinical Investigation, 10.1172/JCI44751, 121:5, (2000-2012), Online publication date: 2-May-2011. Mitra S, Deshmukh A, Sachdeva R, Lu J and Mehta J (2011) Oxidized Low-Density Lipoprotein and Atherosclerosis Implications in Antioxidant Therapy, The American Journal of the Medical Sciences, 10.1097/MAJ.0b013e318224a147, 342:2, (135-142), Online publication date: 1-Aug-2011. Cai T and Cai Y (2011) cis-Ampelopsin E, a Stilbene Isolated from the Seeds of Paeonia suffruticosa, Inhibits Lipopolysaccharide-Stimulated Nitric Oxide Production in RAW 264.7 Macrophages via Blockade of Nuclear Factor-Kappa B Signaling Pathway, Biological and Pharmaceutical Bulletin, 10.1248/bpb.34.1501, 34:9, (1501-1507), . Jiang P, Dai W, Yan S, Chen Z, Xu R, Ding J, Xiang L, Wang S, Liu R and Zhang W (2011) Biomarkers in the early period of acute myocardial infarction in rat serum and protective effects of Shexiang Baoxin Pill using a metabolomic method, Journal of Ethnopharmacology, 10.1016/j.jep.2011.09.049, 138:2, (530-536), Online publication date: 1-Nov-2011. Mitra S, Goyal T and Mehta J (2011) Oxidized LDL, LOX-1 and Atherosclerosis, Cardiovascular Drugs and Therapy, 10.1007/s10557-011-6341-5, 25:5, (419-429), Online publication date: 1-Oct-2011. Haeggström J, Rinaldo-Matthis A, Wheelock C and Wetterholm A (2010) Advances in eicosanoid research, novel therapeutic implications, Biochemical and Biophysical Research Communications, 10.1016/j.bbrc.2010.03.140, 396:1, (135-139), Online publication date: 1-May-2010. Gonsalves C and Kalra V (2010) Hypoxia-Mediated Expression of 5-Lipoxygenase–Activating Protein Involves HIF-1α and NF-κB and MicroRNAs 135a and 199a-5p, The Journal of Immunology, 10.4049/jimmunol.0902594, 184:7, (3878-3888), Online publication date: 1-Apr-2010. Lai Y, Ma L, Huang W, Yu X, Zhang Y, Ji H and Tian J (2010) Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl)phenyl]methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX inhibitors, Bioorganic & Medicinal Chemistry Letters, 10.1016/j.bmcl.2010.10.056, 20:24, (7349-7353), Online publication date: 1-Dec-2010. Sordillo L, Gandy J and Corl C (2010) Thioredoxin reductase attenuates vascular inflammatory responses during oxidative stress, Proceedings of the Nutrition Society, 10.1017/S0029665110001060, 69:OCE3, . Lapenna D, Ciofani G, Pierdomenico S, Neri M, Cuccurullo C, Giamberardino M and Cuccurullo F (2009) Inhibitory activity of salicylic acid on lipoxygenase-dependent lipid peroxidation, Biochimica et Biophysica Acta (BBA) - General Subjects, 10.1016/j.bbagen.2008.09.007, 1790:1, (25-30), Online publication date: 1-Jan-2009. Saha P, Modarai B, Humphries J, Mattock K, Waltham M, Burnand K and Smith A (2009) The monocyte/macrophage as a therapeutic target in atherosclerosis, Current Opinion in Pharmacology, 10.1016/j.coph.2008.12.017, 9:2, (109-118), Online publication date: 1-Apr-2009. Tiwari R, Singh V and Barthwal M (2008) Macrophages: An elusive yet emerging therapeutic target of atherosclerosis, Medicinal Research Reviews, 10.1002/med.20118, 28:4, (483-544), Online publication date: 1-Jul-2008. Nunemaker C, Chen M, Pei H, Kimble S, Keller S, Carter J, Yang Z, Smith K, Wu R, Bevard M, Garmey J and Nadler J (2008) 12-Lipoxygenase-knockout mice are resistant to inflammatory effects of obesity induced by western diet, American Journal of Physiology-Endocrinology and Metabolism, 10.1152/ajpendo.90371.2008, 295:5, (E1065-E1075), Online publication date: 1-Nov-2008. Uozumi N, Kita Y and Shimizu T (2008) Modulation of Lipid and Protein Mediators of Inflammation by Cytosolic Phospholipase A 2 α during Experimental Sepsis , The Journal of Immunology, 10.4049/jimmunol.181.5.3558, 181:5, (3558-3566), Online publication date: 1-Sep-2008. Takeya H and Suzuki K Lipid Mediators and Tissue Factor Expression Recent Advances in Thrombosis and Hemostasis 2008, 10.1007/978-4-431-78847-8_7, (133-146) McCormick M, Gavrila D and Weintraub N (2007) Role of Oxidative Stress in the Pathogenesis of Abdominal Aortic Aneurysms, Arteriosclerosis, Thrombosis, and Vascular Biology, 27:3, (461-469), Online publication date: 1-Mar-2007. Williams M and Nadler J (2007) Inflammatory mechanisms of diabetic complications, Current Diabetes Reports, 10.1007/s11892-007-0038-y, 7:3, (242-248), Online publication date: 1-Jun-2007. Hołowko-Ziółek J, Cięszczyk P, Biliński J, Basak G and Stachowska E (2020) What Model of Nutrition Can Be Recommended to People Ending Their Professional Sports Career? An Analysis of the Mediterranean Diet and the CRON Diet in the Context of Former Athletes, Nutrients, 10.3390/nu12123604, 12:12, (3604) Shen L, Sun Z, Chu S, Cai Z, Nie P, Wu C, Yuan R, Hu L, He B and Pizzo S (2017) Xuezhikang, an extract from red yeast rice, attenuates vulnerable plaque progression by suppressing endoplasmic reticulum stress-mediated apoptosis and inflammation, PLOS ONE, 10.1371/journal.pone.0188841, 12:11, (e0188841) Genard B, Miner P, Nicolas J, Moraga D, Boudry P, Pernet F, Tremblay R and Sun J (2013) Integrative Study of Physiological Changes Associated with Bacterial Infection in Pacific Oyster Larvae, PLoS ONE, 10.1371/journal.pone.0064534, 8:5, (e64534) June 2006Vol 26, Issue 6 Advertisement Article InformationMetrics https://doi.org/10.1161/01.ATV.0000222960.43792.ffPMID: 16709954 Originally publishedJune 1, 2006 PDF download Advertisement
Referência(s)